Ernest Marmer
Long only, special situations

EnteroMedics Device Faces FDA Panel June 17th With Weak Clinical Data

EnteroMedics (NASDAQ:ETRM) is developing a vagus-nerve stimulator to address obesity, and is facing a panel of medical experts Tuesday, June 17th, who will make recommendations about its Maestro device to the FDA for/against its approval for the US market. In recent years, ETRM has conducted two Phase III trials on the device, both of which clearly missed all their efficacy endpoints, resulting in the stock losing 97%+ of its price (from about $30 down to about $0.85). Yet, company PR, a small handful of analysts and some interpretations of recent stock action claim good reason for likelihood of approval nonetheless. A close and sober look at the clinical context is called for.

Phase-III trials' results and trial design...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
PRO Top long ideas returned 21.7% in 2016**
"As a PRO member, we get uniquely valuable perspective that go beyond our quantiative analysis... We rely on PRO to get beyond the numbers quickly and add much needed perspective. It keeps me ahead of the next big thing. - Mark Choate, Malaga Cove Capital"
Mark Choate, Malaga Cove Capital
"Contributors (writers and commentators), often have a long history in the secuirities they opine on and some are clearly well positioned industry participants with detailed industry views that can help provide color on where the skeletons are buried in a particular secuirity and/or industry."
Jim Roumell, Roumell Asset Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details